《大行報告》富瑞下調金斯瑞生物科技(01548.HK)目標價至30元 評級「買入」
富瑞發表研究報告指出,金斯瑞生物科技(01548.HK)上半年收入按年增長26%至3.91億美元,經調整淨虧損1.62億美元,相對於去年同期虧損1.35億美元。非細胞療法收入按年增長14%至2.82億美元,經調整淨利潤率11.9%,低過去年同期13.4%。細胞療法收入升77%至1.1億美元,經調整虧損1.96億美元,去年同期虧損1.68億美元。
該行稱,金斯瑞生物科技預期今年生命科學服務及產品(CRO)業務按年增長12%至18%,生物製劑合約開發及生產組織(CDMO)按年呈低單位數增長,工業合成業務按年增長20%至30%。公司或最快將於2025年下半年實現收支平衡。該行將其目標價由35元下調至30元,評級「買入」。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.